 |
市場調查報告書
商品編碼
1535837
環氧合酶 1 抑制劑市場 - 按類型（選擇性 Cox 1 抑制劑、非選擇性 Cox 1 抑制劑）、應用（發炎性疾病、胃腸道毒性、癌症化學預防）、配銷通路- 全球預測（ 2024 年- 2032 年）Cyclooxygenase 1 Inhibitor Market - By Type (Selective Cox 1 Inhibitor, Non-Selective Cox 1 Inhibitor), Application (Inflammatory Diseases, Gastrointestinal Toxicity, Cancer Chemoprevention), Distribution Channel - Global Forecast (2024 - 2032) |
||||||
由於人口老化的成長和對疼痛管理選擇的認知不斷提高，2024年至2032年全球環加氧酶1抑制劑市場規模將創下7.6%的複合年成長率。環加氧酶 1 抑制劑透過靶向產生前列腺素的 COX-1 酶來減輕疼痛和發炎。
藥物研究的進步正在推動新型 COX-1 抑制劑的開發，其安全性和功效均得到改善。此外，持續的發展確保 COX-1 抑制劑仍然是管理與老化相關的健康問題不可或缺的一部分。根據《2022年世界人口展望》，65歲以上人口的成長速度快於年輕族群。這種人口結構的變化正在增加治療與年齡相關的疼痛和發炎的產品需求。
環氧合酶 1 抑制劑產業按類型、應用、配銷通路和地區分類。
就類型而言，到 2032 年，非選擇性 Cox 1 抑制劑領域的行業規模將大幅成長。研究人員正在探索非選擇性 Cox 1 抑制劑對胃腸道健康的影響，因為它們會影響胃壁並導致不良副作用。此外，持續的進步正在改進非選擇性 COX-1 抑制劑的配方，以在保持有效性的同時增強其安全性。
從應用來看，由於使用量不斷增加以最佳化效益並最大限度地減少潛在副作用，預計從 2024 年到 2032 年，環氧合酶 1 抑制劑在癌症化學預防領域的市佔率將會上升。 COX-1 抑制劑（例如阿斯匹靈）能夠阻斷 COX-1 酶活性，而 COX-1 酶活性與發炎和腫瘤進展有關。研究人員也關注 COX-1 抑制劑如何透過阻止可促進腫瘤發展的發炎性前列腺素的形成來降低癌症風險。
從地區來看，在不斷成長的藥品組合和藥物輸送系統進步的推動下，歐洲環氧合酶 1 抑製劑行業規模預計將在 2024 年至 2032 年間實現強勁成長。阿斯匹靈和布洛芬等 COX-1 抑制劑在很大程度上被整合到更廣泛的疼痛和發炎治療中，進一步反映了它們的多功能性和有效性。同時，藥物傳遞系統的改進正在增強 COX-1 抑制劑的功效和安全性，以確保該地區更好的吸收和有針對性的作用。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 發炎性疾病盛行率增加
- 藥物開發的技術進步
- 癌症盛行率上升
- 提高認知和診斷
- 產業陷阱與挑戰
- 不良反應和安全問題
- 成長動力
- 成長潛力分析
- 報銷場景
- 監管環境
- 技術景觀
- 核心技術
- 鄰近技術
- 2023 年定價分析
- 按地區
- 按關鍵人物
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按類型，2021 - 2032
- 主要趨勢
- 選擇性cox 1抑制劑
- 非選擇性 Cox 1 抑制劑
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 發炎性疾病
- 胃腸道毒性
- 癌症化學預防
- 其他應用
第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥房
- 網路藥房
第 8 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- AbbVie Inc.
- Alembic Limited
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Bayer AG
- Cipla Limited
- Hikma Pharmaceuticals PLC
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- Sabinsa
- Teva Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Limited
- Viatris Inc.
- Zydus Lifesciences Limited
Global Cyclooxygenase 1 Inhibitor Market size will record 7.6% CAGR from 2024 to 2032, due to the growth of the aging population and increasing awareness of pain management options. Cyclooxygenase 1 inhibitors are used to reduce pain and inflammation by targeting the COX-1 enzyme for producing prostaglandins.
Advances in pharmaceutical research are leading to the development of new COX-1 inhibitors with improved safety profiles and efficacy. Furthermore, ongoing evolution is ensuring that COX-1 inhibitors remain integral to managing health issues associated with aging. According to the World Population Prospects 2022, the population above the age of 65 years is growing more rapidly than younger age groups. This demographic shift is increasing the product demand for managing age-related pain and inflammation.
The cyclooxygenase 1 inhibitors industry is segregated into type, application, distribution channel, and region.
In terms of type, the industry size from the non-selective Cox 1 inhibitor segment is set to experience growth at a significant rate through 2032. This is owing to the strong need to address pain and inflammation by inhibiting the COX-1 enzyme. Researchers are exploring the effects of non-selective Cox 1 inhibitors on gastrointestinal health as they can affect the stomach lining and lead to adverse side effects. In addition, ongoing advancements are improving the formulations of non-selective COX-1 inhibitors to enhance their safety profiles while maintaining effectiveness.
By application, the cyclooxygenase 1 inhibitor market share from the cancer chemoprevention segment is projected to rise from 2024 to 2032, fueled by rising usage to optimize the benefits and minimize potential side effects. COX-1 inhibitors, such as aspirin offer the ability to block COX-1 enzyme activity, which is involved in inflammation and tumor progression. Researchers are also focusing on how COX-1 inhibitors might reduce cancer risk by preventing the formation of inflammatory prostaglandins that can promote tumor development.
Regionally, the Europe cyclooxygenase 1 inhibitor industry size is projected to register robust growth between 2024 and 2032, driven by growing pharmaceutical portfolio and advancements in drug delivery systems. COX-1 inhibitors like aspirin and ibuprofen are largely integrated into a wider range of treatments for pain and inflammation, further reflecting their versatility and effectiveness. Simultaneously, improvements in drug delivery systems are enhancing the efficacy and safety of COX-1 inhibitors for ensuring better absorption and targeted actions in the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of inflammatory diseases
- 3.2.1.2 Technological advancements in drug development
- 3.2.1.3 Rising prevalence of cancer
- 3.2.1.4 Increasing awareness and diagnosis
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Adverse effects and safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Reimbursement scenario
- 3.5 Regulatory landscape
- 3.6 Technological landscape
- 3.6.1 Core technologies
- 3.6.2 Adjacent technologies
- 3.7 Pricing analysis, 2023
- 3.7.1 By region
- 3.7.2 By key player
- 3.8 Future market trends
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Selective cox 1 inhibitor
- 5.3 Non-selective Cox 1 inhibitor
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Inflammatory diseases
- 6.3 Gastrointestinal toxicity
- 6.4 Cancer chemoprevention
- 6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacy
- 7.3 Retail pharmacy
- 7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AbbVie Inc.
- 9.2 Alembic Limited
- 9.3 Aurobindo Pharma Limited
- 9.4 Boehringer Ingelheim International GmbH
- 9.5 Bayer AG
- 9.6 Cipla Limited
- 9.7 Hikma Pharmaceuticals PLC
- 9.8 Johnson & Johnson
- 9.9 Novartis AG
- 9.10 Pfizer Inc.
- 9.11 Sabinsa
- 9.12 Teva Pharmaceutical Industries Ltd
- 9.13 Torrent Pharmaceuticals Limited
- 9.14 Viatris Inc.
- 9.15 Zydus Lifesciences Limited
